China National Biotec Group
- All
- News
-
50,000 People Globally Part Of Phase 3 Trial Of Chinese COVID-19 Vaccine
Around 50,000 people, across a number of countries, are participating in phase 3 clinical trials of a COVID vaccine developed by the China National Biotec Group (CNBG), the company said on Saturday in a press release.
-
China To Run "Phase 3" Human Trials Of Coronavirus Vaccine In UAE
China National Biotec Group (CNBG) has won approval to run a large-scale "Phase 3" clinical trial of its novel coronavirus vaccine candidate in the United Arab Emirates (UAE), the company said on Tuesday.
-
Experimental COVID Vaccine Showing Promising Results In Human Trials: Chinese Firm
China National Biotec Group (CNBG) said on Tuesday its experimental coronavirus vaccine has triggered antibodies in clinical trials and the company plans late-stage human trials in foreign countries.
-
50,000 People Globally Part Of Phase 3 Trial Of Chinese COVID-19 Vaccine
Around 50,000 people, across a number of countries, are participating in phase 3 clinical trials of a COVID vaccine developed by the China National Biotec Group (CNBG), the company said on Saturday in a press release.
-
China To Run "Phase 3" Human Trials Of Coronavirus Vaccine In UAE
China National Biotec Group (CNBG) has won approval to run a large-scale "Phase 3" clinical trial of its novel coronavirus vaccine candidate in the United Arab Emirates (UAE), the company said on Tuesday.
-
Experimental COVID Vaccine Showing Promising Results In Human Trials: Chinese Firm
China National Biotec Group (CNBG) said on Tuesday its experimental coronavirus vaccine has triggered antibodies in clinical trials and the company plans late-stage human trials in foreign countries.
